Skip to main content
. Author manuscript; available in PMC: 2018 May 25.
Published in final edited form as: Cancer Cell. 2016 Jun 13;29(6):859–873. doi: 10.1016/j.ccell.2016.05.002

Figure 2. DRD4 Antagonists Are GNS Selective and Show Synergistic Effect with TMZ.

Figure 2

(A) Percent cell viability of four non-NS control cell lines, three NS, and six GNS lines upon treatment with PNU 96415E in dilution series from 0.39 µM to 50 µM. Controls, n = 3, mean ± SEM; NS lines, n = 5–15, mean ± SEM; GNS lines, n = 3–12, mean ± SEM.

(B) Percent cell viability of BJ, three NS, and five GNS lines upon treatment with L-741,742 in dilution series from 0.39 µM to 50 µM. BJ, n = 3, mean ± SEM; NS lines, n = 3–11, mean ± SEM; GNS lines, n = 3–7, mean ± SEM.

(C) Linear regression plot of in vitro LDA for freshly dissociated patient tumor (GBM 686) treated with L-741,742 (10 µM), PNU 96415E (25 µM), and DMSO. Representative phase-contrast image of neurospheres at day 14 in a well seeded with 2,000 cells. Scale bars, 100 µm.

(D) Immunofluorescence staining for VGlut1, βIII-tubulin, and DAPI in NS (hf5205 and hf6539) differentiated in DMSO and L-741,742 for 3 weeks. Scale bars, 100 µm.

(E) Combination index plot for TMZ with L-741,742 or PNU 96415E in GNS. Combination index (CI) plotted against fractions affected (Fa) analyzed using COMPUSYN.

See also Figure S1.